MBX (MBX Biosciences) ROE % Adjusted to Book Value: -7.19% (As of Mar. 2026)


MBX MBX Biosciences Inc MBX
12 GF Score
Price $50.41
! 2 Warning Signs
View Full Analysis

What is MBX Biosciences ROE % Adjusted to Book Value?

MBX Biosciences MBX +4.07% 12 ROE % Adjusted to Book Value is -7.19% as of Mar. 2026. GuruFocus rates MBX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

MBX Biosciences's ROE % for the quarter that ended in Mar. 2026 was -23.31%. MBX Biosciences's PB Ratio for the quarter that ended in Mar. 2026 was 3.24. MBX Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -7.19%.

MBX Biosciences ROE % Adjusted to Book Value Related Terms

MBX Biosciences ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for MBX Biosciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MBX Biosciences ROE % Adjusted to Book Value Chart

MBX Biosciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 -28.01 -7.23

MBX Biosciences Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.91 -19.51 -14.11 -6.07 -7.19

MBX vs ARDX, INBX, MAZE: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, MBX Biosciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MBX Biosciences ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MBX Biosciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where MBX Biosciences's ROE % Adjusted to Book Value falls into.


MBX
12GF Score
MBX Biosciences Inc MBX
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MBX Biosciences ROE % Adjusted to Book Value Calculation

MBX Biosciences's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-27.76% / 3.84
=-7.23%

MBX Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-23.31% / 3.24
=-7.19%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -7.19% mean?
MBX Biosciences (MBX) has a ROE % Adjusted to Book Value of -7.19% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on MBX Biosciences and its competitors.
Is MBX Biosciences' ROE % Adjusted to Book Value too high?
MBX Biosciences' current ROE % Adjusted to Book Value is -7.19%. Overall, MBX Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does MBX Biosciences' ROE % Adjusted to Book Value compare to ARDX and INBX?
MBX Biosciences' ROE % Adjusted to Book Value of -7.19% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on MBX Biosciences and its competitors. MBX Biosciences's current ROE % Adjusted to Book Value is -7.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MBX Biosciences stock overvalued right now?
MBX Biosciences (MBX) has a current ROE % Adjusted to Book Value of -7.19%. The current ROE % Adjusted to Book Value is -7.19%. MBX Biosciences' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For MBX Biosciences (MBX), the current ROE % Adjusted to Book Value is -7.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MBX Biosciences Business Description

Address 11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
12GF Score

Get the complete analysis for MBX

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$50.41
Price